7829.TWO Yoda Pharmaceuticals Inc.

Healthcare Drug Manufacturers - Specialty & Generic Taiwan OTC Exchange
48.70 TWD
Close of Nov 6, 2026
36.20 62.20
Market cap
TWD 4.84B
P/E
-
P/B
4.71x
ROE
-41.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 7829.TWO undervalued?

Graham number

The Graham number of Yoda Pharmaceuticals Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Yoda Pharmaceuticals Inc. fundamental analysis

No fundamental analysis for Yoda Pharmaceuticals Inc. yet.

Yoda Pharmaceuticals Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Yoda Pharmaceuticals Inc.

Yoda Pharmaceuticals Inc., an AI-driven company, focuses on development of drugs targeting central nervous system disorders. The company's flagship drug, YA-101 is in Phase 2 clinical trial for the treatment of multiple system atrophy. It is also involved in the development pipeline includes drugs in the field of neurological and psychiatric disorders and cerebrovascular diseases, targeting conditions, such as schizophrenia, Alzheimer's disease, Parkinson"s disease, Autism, …

Full company profile